Literature DB >> 20461816

Reply: Based on the available randomized trial patients should say no to glutathione for Parkinson's disease.

Michael S Okun, Anthony Lang, Joseph Jankovic.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20461816     DOI： 10.1002/mds.23021

Source DB:  PubMed          Journal:  Mov Disord        ISSN： 0885-3185            Impact factor:   10.338


× No keyword cloud information.
  4 in total

Review 1.  Pathogenesis-targeted, disease-modifying therapies in Parkinson disease.

Authors:  Amaal AlDakheel; Lorraine V Kalia; Anthony E Lang
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 2.  Mechanisms for alternative treatments in Parkinson's disease: acupuncture, tai chi, and other treatments.

Authors:  Bijan D Ghaffari; Benzi Kluger
Journal:  Curr Neurol Neurosci Rep       Date:  2014-06       Impact factor: 5.081

Review 3.  Animal models of Parkinson's disease: a gateway to therapeutics?

Authors:  Weidong Le; Pavani Sayana; Joseph Jankovic
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 4.  Dysregulation of glutathione homeostasis in neurodegenerative diseases.

Authors:  William M Johnson; Amy L Wilson-Delfosse; John J Mieyal
Journal:  Nutrients       Date:  2012-10-09       Impact factor: 5.717
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.